



# MARKET RELEASE

20 October 2011

Pharmaxis Ltd

## SUSPENSION FROM OFFICIAL QUOTATION

The securities of Pharmaxis Ltd (the "Company") will be suspended from quotation immediately, at the request of the Company, pending the release of an announcement.

Security Code: PXS

A handwritten signature in black ink, appearing to read 'C. Bill'.

Cameron Bill  
Adviser, Listings (Sydney)

For personal use only

19 October 2011

ASX Limited  
Adviser, Issuers (Sydney)  
Exchange Centre  
20 Bridge Street  
Sydney NSW 2000

Attention: Mr Cameron Bill

Dear Mr Bill,

### **Request for Voluntary Suspension**

We refer to Pharmaxis Ltd's (**Pharmaxis**) request for a trading halt on 17 October 2011. That trading halt is due to be lifted prior to commencement of trading on Thursday 20 November 2011.

Pharmaxis has not yet received the definitive notification of the outcome of the re-examination of Bronchitol<sup>®</sup> for the treatment of cystic fibrosis which is due to be released on the evening of 21 October 2011 (Australian time) when the European Committee for Medicinal Products for Human Use releases notes of its meetings.

As foreshadowed in our request letter dated 17 October 2011, Pharmaxis requests a two day voluntary suspension of trading in its shares, to commence before the commencement of trading on 20 October 2011 and to continue until to commencement of trading on 24 October 2011 or the announcement of the outcome of the re-examination of Bronchitol<sup>®</sup> for the treatment of cystic fibrosis, whichever occurs earlier.

In accordance with ASX Listing Rule 17.2, Pharmaxis confirms that it is not aware of any reason why the voluntary suspension should not be granted.

Yours sincerely,



David McGarvey  
Chief Financial Officer/ Company Secretary

For personal use only